Simplify Logo

Full-Time

Senior Scientist

Confirmed live in the last 24 hours

Absci

Absci

51-200 employees

Biotech company specializing in protein production

Data & Analytics
Hardware
AI & Machine Learning
Biotechnology
Healthcare

Compensation Overview

$127k - $165kAnnually

+ Equity Package + Bonus

Senior, Expert

Vancouver, WA, USA

Category
Lab & Research
Interdisciplinary Research
Life Sciences
Required Skills
Communications
Requirements
  • Ph.D. or equivalent advanced degree in Pharmacology, Immunology/Inflammation, Oncology, Physiology, or related disciplines with at least 5+ years of post-PhD academic and / or industry experience in immunology, immune-mediated inflammatory diseases or related field establishing direct experimental experience with complex biology of inflammatory diseases
  • Extensive experience with flow-based in-depth characterization of immune cell populations in blood and tissue samples.
  • Experience with cell-based assays, ELISA, MSD, qPCR, microscopy, histology/pathology (e.g. IF/IHC/ISH).
  • Demonstrated expertise with complex 2D/3D functional cell-based and tissue-based assays to investigate disease biology and PK/PD relationship.
  • Experience with leveraging complex data sets to characterize and establish a drug’s therapeutic mechanisms of action
  • Ability to be hands on and working in the lab, manage scientists, write protocols, execute studies leveraging Absci’s in house capabilities
  • Experience working with project/research teams with functional responsibility to propose strategy, analyze, interpret, and present complex data to inform decisions
  • Ability to collaborate in writing protocols and reports
  • Outstanding communication skills with demonstrated ability to make effective presentations in a broad range of settings
  • Detail-oriented and organized, with strong interpersonal skills for clear and effective communication.
Responsibilities
  • Work in a dynamic and collaborative Disease Biology team that works closely with key stakeholders across our interdisciplinary R&D teams.
  • Coordinate, design, organize & conduct preclinical in vitro, ex vivo and in vivo studies to advance our internal therapeutic programs.
  • Generate, analyze, and interpret complex data, provide evaluation of PK-PD-efficacy relationships, exploration of PD and predictive biomarkers and elucidation of drug’s MoA.
  • Identify and evaluate (new) in vivo models and technologies to enable novel target validation and lead discovery screening, perform lab-based activities to support a variety of research efforts towards MoA understanding and therapeutic lead development.
  • Establish and manage interactions with vendors and CROs and work closely with key expertise areas to generate necessary studies and reagents for in vivo screening.
  • Serve as Disease Biology SME on multiple project teams, conduct and trouble-shoot experiments, analyze and interpret data and work cross functionally with colleagues to identify and mitigate risks and effectively advance therapeutic programs.
  • Help build complex in vitro and ex vivo research and development capabilities.
  • Author and review clearly articulated SoPs, study reports, and data presentations.

AbSci focuses on improving protein expression and biomanufacturing in the biotech industry. Its main product is an advanced protein expression platform that uses a semi-oxidizing cytoplasm and a dual inducible promoter system, allowing for better control over protein production rates. This results in higher quality and more efficient drug manufacturing. A key feature of AbSci's offerings is SoluPure, a method that simplifies protein purification without chromatography, speeding up the production process and reducing costs. AbSci's workflow can create cell lines that produce active proteins in as little as three months, which is much faster than traditional methods. Unlike its competitors, AbSci aims to replace older mammalian expression systems with its more efficient solutions. The company's goal is to enhance drug discovery and manufacturing processes for pharmaceutical and biotech companies, ultimately transforming the production of biologics.

Company Stage

IPO

Total Funding

$324.3M

Headquarters

Vancouver, Washington

Founded

2011

Growth & Insights
Headcount

6 month growth

-1%

1 year growth

-7%

2 year growth

-11%
Simplify Jobs

Simplify's Take

What believers are saying

  • AbSci's recent $86M public stock offering and strategic partnerships, such as with AstraZeneca, highlight strong financial backing and growth potential.
  • The company's ability to generate cell lines producing active protein products in as little as three months accelerates drug development timelines, offering significant time and cost savings.
  • AbSci's collaboration with PrecisionLife to develop an AI-enabled drug pipeline demonstrates their commitment to innovation and addressing unmet medical needs.

What critics are saying

  • The biotech industry is highly competitive, and AbSci must continuously innovate to maintain its edge over established and emerging competitors.
  • Relying heavily on strategic partnerships and collaborations could pose risks if these relationships falter or fail to deliver expected outcomes.

What makes Absci unique

  • AbSci's SoluPure technology offers a chromatography-free purification method, significantly reducing bottlenecks in protein production compared to traditional techniques.
  • Their advanced protein expression platform with a semi-oxidizing cytoplasm and dual inducible promoter system allows for precise control over protein production rates, setting them apart from competitors.
  • AbSci's integration of generative AI in drug discovery and biomanufacturing positions them uniquely in the biotech industry, combining cutting-edge technology with traditional biopharmaceutical processes.